Movement Alert｜DotBio-B Falls 5.15% in Regular Trading, Biotech Sector Broadly Weakens After Prior Session Rally

Market Focus07-21 10:17

On July 21, DotBio-B declined 5.15% in regular trading, trading at 230.2 HKD/share, with turnover of approximately HKD 54.22 million. The broader biotechnology sector showed widespread weakness, with BEIGENE down 1.78%, AKESO down 2.52%, INNOVENT BIO down 2.11%, SKB BIO down 0.79%, and 3SBIO down 2.07%.

The pullback follows the stock's strong rally in the prior session, during which shares surged as much as 15% after the company's B7-H3 ADC DB-1311/BNT324 was proposed for breakthrough therapy designation by CDE for the treatment of metastatic castration-resistant prostate cancer, and initial Phase I/IIa clinical data for DB-1310 in advanced solid tumors was disclosed at ASCO. Sector-wide selling pressure amid a generally weaker biotech tape appears to have triggered profit-taking following the previous day's significant gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104410900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104410900","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DotBio-B Falls 5.15% in Regular Trading, Biotech Sector Broadly Weakens After Prior Session Rally","media":"Market Focus","content":"<p><p>On July 21, DotBio-B declined 5.15% in regular trading, trading at 230.2 HKD/share, with turnover of approximately HKD 54.22 million. The broader biotechnology sector showed widespread weakness, with BEIGENE down 1.78%, AKESO down 2.52%, INNOVENT BIO down 2.11%, SKB BIO down 0.79%, and 3SBIO down 2.07%.</p><p>The pullback follows the stock's strong rally in the prior session, during which shares surged as much as 15% after the company's B7-H3 ADC DB-1311/BNT324 was proposed for breakthrough therapy designation by CDE for the treatment of metastatic castration-resistant prostate cancer, and initial Phase I/IIa clinical data for DB-1310 in advanced solid tumors was disclosed at ASCO. Sector-wide selling pressure amid a generally weaker biotech tape appears to have triggered profit-taking following the previous day's significant gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DotBio-B Falls 5.15% in Regular Trading, Biotech Sector Broadly Weakens After Prior Session Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DotBio-B Falls 5.15% in Regular Trading, Biotech Sector Broadly Weakens After Prior Session Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-21 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 21, DotBio-B declined 5.15% in regular trading, trading at 230.2 HKD/share, with turnover of approximately HKD 54.22 million. The broader biotechnology sector showed widespread weakness, with BEIGENE down 1.78%, AKESO down 2.52%, INNOVENT BIO down 2.11%, SKB BIO down 0.79%, and 3SBIO down 2.07%.</p><p>The pullback follows the stock's strong rally in the prior session, during which shares surged as much as 15% after the company's B7-H3 ADC DB-1311/BNT324 was proposed for breakthrough therapy designation by CDE for the treatment of metastatic castration-resistant prostate cancer, and initial Phase I/IIa clinical data for DB-1310 in advanced solid tumors was disclosed at ASCO. Sector-wide selling pressure amid a generally weaker biotech tape appears to have triggered profit-taking following the previous day's significant gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1104410900","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104410900","pubTimestamp":1784600232,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 21, DotBio-B declined 5.15% in regular trading, trading at 230.2 HKD/share, with turnover of approximately HKD 54.22 million. The broader biotechnology sector showed widespread weakness, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势警报|DotBio-B 常规交易中下跌 5.15%，生物技术板块在前一交易日上涨后普遍走弱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 21, DotBio-B declined 5.15% in regular trading, trading at 230.2 HKD/share, with turnover of approximately HKD 54.22 million. The broader biotechnology sector showed widespread weakness, with BEIGENE down 1.78%, AKESO down 2.52%, INNOVENT BIO down 2.11%, SKB BIO down 0.79%, and 3SBIO down 2.07%.The pullback follows the stock's strong rally in the prior session, during which shares surged as much as 15% after the company's B7-H3 ADC DB-1311/BNT324 was proposed for breakthrough therapy designation by CDE for the treatment of metastatic castration-resistant prostate cancer, and initial Phase I/IIa clinical data for DB-1310 in advanced solid tumors was disclosed at ASCO. Sector-wide selling pressure amid a generally weaker biotech tape appears to have triggered profit-taking following the previous day's significant gains.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104410900","isCrawlerRequest":true}